TOUR-006 is under clinical development by Tourmaline Bio and currently in Phase II for Atherosclerosis. According to GlobalData, Phase II drugs for Atherosclerosis have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TOUR-006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TOUR-006 overview

TOUR-006 is under development for thyroid eye disease (TED), chronic kidney disease and atherosclerotic cardiovascular disease (ASCVD). The drug candidate is a new biological entity (NBE). It is administered through subcutaneous route. It is a human antibody that acts by targeting Interleukin 6. It was under development for the treatment of Crohn’s disease, rheumatoid arthritis and systemic lupus erythematosus by Pfizer

Tourmaline Bio overview

Tourmaline Bio (Tourmaline), formerly Talaris Therapeutics Inc, is a late-stage biotechnology company that develops transformative medicines for immune diseases. The company’s lead drug candidate TOUR006, is an anti-interleukin-(IL-6) antibody that exhibits differentiated properties including high binding affinity to interleukin 6 (IL-6) and a long half-life that treats thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). It’s anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody also treats autoimmune and inflammatory diseases. Tourmaline is headquartered in New York city, New York, the US.

For a complete picture of TOUR-006’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.